{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:24:17Z","timestamp":1793075057021,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T00:00:00Z","timestamp":1281571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s10096-010-1013-0","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T04:29:19Z","timestamp":1281500959000},"page":"1387-1394","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort"],"prefix":"10.1007","volume":"29","author":[{"given":"J. W.","family":"Hiemenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. I.","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Y.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Saah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Sable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Chodakewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Saddier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"DiNubile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. F.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,12]]},"reference":[{"key":"1013_CR1","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1086\/323895","volume":"33","author":"N Singh","year":"2001","unstructured":"Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692\u20131696","journal-title":"Clin Infect Dis"},{"key":"1013_CR2","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358\u20134366","journal-title":"Blood"},{"key":"1013_CR3","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jlts.2002.36239","volume":"8","author":"J Fort\u00fan","year":"2002","unstructured":"Fort\u00fan J, Mart\u00edn-D\u00e1vila P, Moreno S, De Vicente E, Nu\u00f1o J, Candelas A, B\u00e1rcena R, Garc\u00eda M (2002) Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 8:1065\u20131070","journal-title":"Liver Transpl"},{"key":"1013_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1086\/344906","volume":"36","author":"EA Hagen","year":"2003","unstructured":"Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S, Schuster SJ, Stadtmauer EA, Schuster MG (2003) High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 36:9\u201315","journal-title":"Clin Infect Dis"},{"key":"1013_CR5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.21488","volume":"84","author":"R Parody","year":"2009","unstructured":"Parody R, Martino R, S\u00e1nchez F, Subir\u00e1 M, Hidalgo A, Sierra J (2009) Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 84:571\u2013578","journal-title":"Am J Hematol"},{"key":"1013_CR6","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","volume":"41","author":"GK Abruzzo","year":"1997","unstructured":"Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal K (1997) Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41:2333\u20132338","journal-title":"Antimicrob Agents Chemother"},{"key":"1013_CR7","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.44.9.2310-2318.2000","volume":"44","author":"GK Abruzzo","year":"2000","unstructured":"Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H (2000) Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 44:2310\u20132318","journal-title":"Antimicrob Agents Chemother"},{"key":"1013_CR8","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1128\/AAC.45.12.3474-3481.2001","volume":"45","author":"JC Bowman","year":"2001","unstructured":"Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM (2001) Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45:3474\u20133481","journal-title":"Antimicrob Agents Chemother"},{"key":"1013_CR9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","volume":"39","author":"J Maertens","year":"2004","unstructured":"Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563\u20131571","journal-title":"Clin Infect Dis"},{"key":"1013_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/320876","volume":"33","author":"JH Rex","year":"2001","unstructured":"Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, Carillo-Munoz AJ, Chavanet P, Cloud GA, Denning DW, de Pauw BE, Edwards JE Jr, Hiemenz JW, Kauffman CA, Lopez-Berestein G, Martino P, Sobel JD, Stevens DA, Sylvester R, Tollemar J, Viscoli C, Viviani MA, Wu T (2001) Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 33:95\u2013106","journal-title":"Clin Infect Dis"},{"key":"1013_CR11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","volume":"97","author":"DW Denning","year":"1994","unstructured":"Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect HR, Dockery B, Dismukes WE, Stevens DA (1994) NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135\u2013144","journal-title":"Am J Med"},{"key":"1013_CR12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1086\/345441","volume":"36","author":"N Singh","year":"2003","unstructured":"Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, Tollemar JG, Dominguez EA, Yu CM, Paterson DL, Husain S, Kusne S, Linden P (2003) Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36:46\u201352","journal-title":"Clin Infect Dis"},{"key":"1013_CR13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0163-4453(98)80173-4","volume":"37","author":"DW Denning","year":"1998","unstructured":"Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37:173\u2013180","journal-title":"J Infect"},{"key":"1013_CR14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","volume":"27","author":"M Ellis","year":"1998","unstructured":"Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, Sylvester R, Meis J, Boogaerts M, Selleslag D, Krcmery V, von Sinner W, MacDonald P, Doyen C, Vandercam B (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406\u20131412","journal-title":"Clin Infect Dis"},{"key":"1013_CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408\u2013415","journal-title":"N Engl J Med"},{"key":"1013_CR16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/clinids\/21.5.1145","volume":"21","author":"BA Oppenheim","year":"1995","unstructured":"Oppenheim BA, Herbrecht R, Kusne S (1995) The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21:1145\u20131153","journal-title":"Clin Infect Dis"},{"key":"1013_CR17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","volume":"26","author":"TJ Walsh","year":"1998","unstructured":"Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383\u20131396","journal-title":"Clin Infect Dis"},{"key":"1013_CR18","first-page":"635","volume":"24","author":"MH White","year":"1997","unstructured":"White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Du Mond C, Mamelok RD, Bowden RA (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635\u2013642","journal-title":"Clin Infect Dis"},{"key":"1013_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","volume":"34","author":"S Ascioglu","year":"2002","unstructured":"Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7\u201314","journal-title":"Clin Infect Dis"},{"key":"1013_CR20","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/323020","volume":"33","author":"D Caillot","year":"2001","unstructured":"Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33:e83\u2013e90","journal-title":"Clin Infect Dis"},{"key":"1013_CR21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563\u2013571","journal-title":"Clin Infect Dis"},{"key":"1013_CR22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst H-A, Thi\u00e9baut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 44:1289\u20131297","journal-title":"Clin Infect Dis"},{"key":"1013_CR23","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/521942","volume":"45","author":"DW Denning","year":"2007","unstructured":"Denning DW (2007) Comparison of 2 studies of treatment of invasive aspergillosis. Clin Infect Dis 45:1106\u20131108","journal-title":"Clin Infect Dis"},{"key":"1013_CR24","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/517849","volume":"44","author":"L Pagano","year":"2007","unstructured":"Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, Offidani M, Nosari A (2007) Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality\u2014SEIFEM-C Report. Clin Infect Dis 44:1524\u20131525","journal-title":"Clin Infect Dis"},{"key":"1013_CR25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","volume":"79","author":"TF Patterson","year":"2000","unstructured":"Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR (2000) Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79:250\u2013260","journal-title":"Medicine (Baltimore)"},{"key":"1013_CR26","first-page":"528","volume":"87","author":"M Subir\u00e1","year":"2002","unstructured":"Subir\u00e1 M, Martino R, Franquet T, Puzo C, Alt\u00e9s A, Sureda A, Brunet S, Sierra J (2002) Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 87:528\u2013534","journal-title":"Haematologica"},{"key":"1013_CR27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb04825.x","volume":"86","author":"W Mills","year":"1994","unstructured":"Mills W, Chopra R, Linch DC, Goldstone AH (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 86:754\u2013760","journal-title":"Br J Haematol"},{"key":"1013_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1086\/320895","volume":"33","author":"JH Powers","year":"2001","unstructured":"Powers JH (2001) Counterpoint: alternative trial designs for antifungal drugs\u2014time to talk. Clin Infect Dis 33:107\u2013109","journal-title":"Clin Infect Dis"},{"key":"1013_CR29","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","volume":"342","author":"K Benson","year":"2000","unstructured":"Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878\u20131886","journal-title":"N Engl J Med"},{"key":"1013_CR30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0002-9343(82)90815-4","volume":"72","author":"H Sacks","year":"1982","unstructured":"Sacks H, Chalmers TC, Smith H Jr (1982) Randomized versus historical controls for clinical trials. Am J Med 72:233\u2013240","journal-title":"Am J Med"},{"key":"1013_CR31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"TJ Walsh","year":"2007","unstructured":"Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2\u201312","journal-title":"Clin Infect Dis"},{"key":"1013_CR32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","volume":"44","author":"A Upton","year":"2007","unstructured":"Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA (2007) Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44:531\u2013540","journal-title":"Clin Infect Dis"},{"key":"1013_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2007.10.002","volume":"27","author":"J Groetzner","year":"2008","unstructured":"Groetzner J, Kaczmarek I, Wittwer T, Strauch J, Meiser B, Wahlers T, Daebritz S, Reichart B (2008) Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 27:1\u20136","journal-title":"J Heart Lung Transplant"},{"key":"1013_CR34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","volume":"64","author":"C Viscoli","year":"2009","unstructured":"Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J; Infectious Disease Group of the EORTC (2009) An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 64:1274\u20131281","journal-title":"J Antimicrob Chemother"},{"key":"1013_CR35","author":"R Herbrecht","year":"2010","unstructured":"Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C (2010) Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. doi: 10.1038\/bmt.2009.334","journal-title":"Bone Marrow Transplant"},{"key":"1013_CR36","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMc061720","volume":"356","author":"PE Verweij","year":"2007","unstructured":"Verweij PE, Mellado E, Melchers WJG (2007) Multiple-triazole-resistant aspergillosis. N Engl J Med 356:1481\u20131483","journal-title":"N Engl J Med"},{"key":"1013_CR37","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","volume":"15","author":"SJ Howard","year":"2009","unstructured":"Howard SJ, Cerar D, Anderson MJ, Albarrag AM, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW (2009) Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15:1068\u20131076","journal-title":"Emerg Infect Dis"},{"key":"1013_CR38","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/508455","volume":"43","author":"NG Almyroudis","year":"2006","unstructured":"Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH (2006) Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 43:1449\u20131455","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1013_CR39","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1080\/13693780902718057","volume":"47","author":"M Miceli","year":"2009","unstructured":"Miceli M, Anaissie E (2009) Clinical trial design for invasive aspergillosis: time to cast a different mold. Med Mycol 47(Suppl 1):S343\u2013S348","journal-title":"Med Mycol"},{"key":"1013_CR40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jinf.2004.05.011","volume":"50","author":"NA Kartsonis","year":"2005","unstructured":"Kartsonis NA, Saah AJ, Lipka JC, Taylor AF, Sable CA (2005) Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50:196\u2013205","journal-title":"J Infect"},{"key":"1013_CR41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1705559","volume":"39","author":"A Safdar","year":"2007","unstructured":"Safdar A, Rodriguez G, Rolston KV, O\u2019Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP (2007) High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 39:157\u2013164","journal-title":"Bone Marrow Transplant"},{"key":"1013_CR42","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/jac\/dkn069","volume":"61","author":"RE Lewis","year":"2008","unstructured":"Lewis RE, Albert ND, Kontoyiannis DP (2008) Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 61:1140\u20131144","journal-title":"J Antimicrob Chemother"},{"key":"1013_CR43","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","volume":"48","author":"RF Betts","year":"2009","unstructured":"Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA; Caspofungin High-Dose Study Group (2009) A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48:1676\u20131684","journal-title":"Clin Infect Dis"},{"key":"1013_CR44","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","volume":"110","author":"D Caillot","year":"2007","unstructured":"Caillot D, Thi\u00e9baut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larch\u00e9 J, Monchecourt F, Alfandari S, Mahi L (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110:2740\u20132746","journal-title":"Cancer"},{"key":"1013_CR45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.leu.2405065","volume":"22","author":"II Raad","year":"2008","unstructured":"Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY (2008) Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:496\u2013503","journal-title":"Leukemia"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1013-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-010-1013-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1013-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:34:20Z","timestamp":1559122460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-010-1013-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,12]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1007\/s10096-010-1013-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,12]]}}}